Overview

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (what the body does to the medication), safety and antiviral activity to support dose recommendations by body weight of darunavir with low-dose ritonavir (DRV/rtv), in combination with other antiretroviral drugs (ARVs), in treatment-experienced Human immunodeficiency virus 1 (HIV 1) infected children.
Phase:
Phase 2
Details
Lead Sponsor:
Tibotec Pharmaceuticals, Ireland
Collaborator:
Tibotec Pharmaceutical Limited
Treatments:
Antiviral Agents
Darunavir
Ritonavir